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Aim: Experimental and clinical studies showed that the administration of cyclophosphamide (Cy) in low doses leads to an enhancement 
of the antitumor immune response. Our objective was to study the modulation, if any, by low dose Cy, of T regulatory (Treg) and natural 
killer T (NKT) I cells, two cell populations of the innate immune response with opposing effects on the tumors, in a rat B cell lymphoma 
model. Methods: Inbred e rats were challenged s.c. with L-TACB lymphoma and on day 14 animals were distributed in two groups. 
Treated: injected i.p. with cyclophosphamide (10mg/kg of body weight) and Control: injected i.p. with saline. Blood samples were taken 
from days 0 to 21 and the percentage of T regulatory and natural killer T I cells were determined by flow cytometry. Results: We found 
that the increase of natural and inducible T regulatory cells of peripheral blood achieved during tumor growth was significantly down-
regulated by cyclophosphamide. On the contrary, natural killer T I cells were not modulated by the treatment. Conclusion: The antimeta-
static effect of a single low dose of Cy would be due, at least in part, to downregulation of natural and inducible T regulatory cells.
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The mechanisms of peripheral tolerance that control 
the quality and intensity of immune responses are ex-
erted by different types of T cells with regulatory function 
which include specialized subsets of CD4+, CD8+, double 
negative (CD4-CD8-) CD3+, γδ T cells, and natural killer T 
(NKT) cells [1, 2] . Among these, natural T regulatory cells 
(Tregs) were first described in the 1970s by Gershon [3]. 
They were originally identified in mice [4] but then, they 
were also described in rats [5] and humans [6]. Tregs 
exert their suppressive activity in an antigen-nonspecific 
way called “bystander suppression” [2]. They suppress 
a wide variety of immune cells including naive and 
memory CD4+ and CD8+ T cells, B cells, monocytes, and 
dendritic cells [7–12]. Tregs are characte rized by the 
constitutive expression of several activation markers 
as CTLA-4 (CD152) and Foxp3, among others [13–15]. 
However, Foxp3 is the most specific marker for natural 
Tregs playing a precise role in the development and 
function of natural CD4+CD25+ Tregs [13, 14]. Another 
subset of regulatory cells are the Type 1 regulatory cells 
(Tr1) that are defined by their ability to produce high 
levels of IL-10 and transforming growth factor-β (TGF-β)
[16–17], utilizing those cytokines to suppress Th1 and 
Th2-mediated immune responses. Tr1 cells are induc-
ible, antigen-specific and express normal levels of acti-
vation markers such as CD25, following TCR-mediated 
stimulation. Other important regulators of the immune re-
sponse are NKT cells [19]. This cell population expresses 
both functional TCR αβ chains, and NK receptors, such 
as NK1.1. The cells that recognize antigens presented 
by the nonpolymorfic MHC class I-like molecule CD1d 
are true NKT cells [20]. Although type I NKT cells have 
NK-like cytolytic activity, they are considered regulators 
of immune responses because they rapidly produce 
large amounts of Th1 and Th2 cytokines in autoimmune 
disease, infectious disease, and cancer. Activated NKT 
cells induce cell death in tumor cells through the expres-
sion of cell-death-inducing effector molecules [21].
Both, experimental and clinical studies, revealed that 
cyclophosphamide (Cy), an alkylating agent commonly 
used in cancer chemotherapy [22], exerts an apparently 
paradoxical effect on host immune responses [23]. High 
doses of Cy usually bring about an impairment of the 
host defense mechanisms, along with the reduction 
of primary tumor mass, therefore leading to severe im-
munosuppression. However, the administration of low 
doses of Cy leads to an enhancement of the immune 
response, frequently causing tumor rejection [24, 25].
Our previous results in a rat B-cell lymph oma model 
(L-TACB) showed that a single low-dose Cy, admini stered 
to rats bearing already grown lymphomas, inhibited metas-
tasis development [26]. The antimetastatic action of Cy was 
mediated by immunomodulation [27]. We demonstrated 
that IL-10 was the main factor responsible for the induc-
tion and development of immunosuppression in L-TACB-
bearing hosts [28, 29]. In fact, Cy induced a Th2/Th1 switch 
in the cytokine profile and increased the proliferative rate 
of spleen cells [30].
Considering the already demonstrated immuno-
modulatory effect of low-dose Cy in a B-cell lymphoma 
tumor model and taking into account that Treg and NKT 
I cells may be involved in the regulation of the antitumor 
immune response, we decided to evaluate if low-dose 
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Cy treatment was able to modulate those lymphocyte 
subpopulations in the same tumor model. Moreover, 
it has been suggested that Tregs and NKT I might 
regulate each other. Treg cells suppress the anti-tumor 
effect and reduce the number of NKT I cells. At the same 
time, NKT I cells regulate Treg cell function [20].
MATERIALS AND METHODS
Mice. Ten to twelve weeks old female inbred IIM 
e/Fm rats (e rats) [31] were housed and cared at the ani-
mal facilities of the School of Medical Sciences, National 
University of Rosario. Animals were fed commercial chow 
and water ad libitum and were maintained in a 12 h light/
dark cycle. All the experiments were done during the first 
half of the light cycle and in accordance with animal care 
standards of the institution, which complies with the guide-
lines issued by the Canadian Council on Animal Care [32].
Tumor. L-TACB is a poorly differentiated B-cell lym-
phoma that arose spontaneously in an inbred e rat [33] and 
metastasizes exclusively to regional lymph nodes when 
injected subcutaneously [26]. This tumor is maintained 
by serial subcutaneous trocar implantation of 1 mm3 tumor 
fragments (approximately 106 cells) in syngeneic rats.
Drugs. Cyclophosphamide (Cy) (Filaxis Lab., 
Argentina) was dissolved in sterile distilled water 
to a concentration of 20 mg/ml and injected at a dose 
of 10 or 20 mg/kg of body weight.
Experimental model. Circulating T regulatory and 
NKT I cells were quantified during tumor evolution in in-
dividual experiments. Inbred e rats were inoculated with 
L-TACB s.c. (day 0). On day 14 animals were distributed 
in two groups: control animals injected i.p. with saline and 
animals treated with a single low dose Cy of 10 mg/kg i.p. 
Blood samples were obtained on days 0; 7; 14 and 21, 
and were processed for flow cytometry analysis with the 
antibodies to the appropriated markers. Different popula-
tions of CD4+CD25+ Tregs were identified: CTLA-4+, Foxp3+ 
and IL-10+ in both experimental groups. Also, we quantified 
NKT I cells using anti-TCR and anti-CD161 antibodies.
Tregs and NKT I cells quantification. Blood 
samples from the tail vein were obtained using EDTA 
as anticoagulant. Peripheral blood mononuclear cells 
were isolated from peripheral blood samples by centrifu-
gation, using Ficoll-Paque density gradient (Ficoll-Paque 
PLUS, GE Healthcare, Uppsala, Sweden). The following 
antibodies were used for immunophenoty ping: CD4-PE-
Cy5 (BD Pharmingen, USA), CD25-FITC (Serotec, UK), 
CD152-RPE (Serotec, UK), Foxp3-PE (eBioscience, USA), 
IL-10-PE (BD Pharmingen, USA), TCR-RPE (Serotec, UK), 
CD161-FITC (Serotec, UK). Samples were fixed in 1% (wt/
vol) paraformaldehyde and analyzed on a Coulter Epics XL 
(Coulter Corp. Miami, FL, USA). Cells were permeabilized 
using saponin (0.1% w/v in PBS). Acquired data were 
analyzed with WinMD1 2.8 data analysis software (Scripps 
Research Institute, La Jolla, Ca, USA).
Statistics. Non-Parametric ANOVA, Mann — 
Whitney’s U tests were utilized using GraphPad Prism  
version 3.03 (GraphPad Software, San Diego, CA). Dif-
ferences between groups were considered significant 
when P < 0.05.
RESULTS AND DISCUSSION
First, we studied the kinetics of different subsets 
of Tregs during tumor growth evolution and after the 
treatment with low dose Cy. We observed an increase 
during tumor growth in the percentage of the three cell 
subsets analyzed (Fig. 1). 
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Fig. 1. Effect of cyclophosphamide on circulating Tregs cells 
during tumor evolution [median (range)]. a) CD4+CD25+CTLA-4+ 
/ CD4+ (%): Kruskal — Wallis Test, P <0.001; Mann — Whitney 
Test, day 21 vs day 0: P < 0.001; day 21: Control vs Cy: ns. b) 
CD4+CD25+Foxp3+ / CD4+ (%):  Kruskal — Wallis Test, P < 0.001; 
Mann — Whitney Test, day 21 vs day 0: P <0.05; day 14 vs day 7 and 
vs day 21: ns; day 21: Control vs Cy: P < 0.01. c) CD4+CD25+IL-10+ 
/ CD4+ (%): Kruskal — Wallis Test, P < 0.001; Mann — Whitney 
Test, day 21 vs day 0: P <0.01; day 21: Control vs Cy: P < 0.05
The percentage of CD4+CD25+CTLA-4+ cells increased 
during tumor growth (P < 0.01); indeed, the levels of these 
cells on day 21 were higher than those on day 0 [% me-
dian (range); day 0: 0.0 (0–0) vs. day 21: 0.4 (0.2–1.4); 
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P < 0.001]. At the end of the experiment, the percent-
age of CD4+CD25+CTLA-4+cells in animals treated with 
Cy was lower than that of controls, but they did not dif-
fer between each other [Day 21: Control 0.4 (0.2–1.4) 
vs Cy: 0.3 (0.1–0.9); ns] (Fig. 1, a). The percentage 
of CD4+CD25+Foxp3+ cell subset increased throughout 
the experiment (P < 0.001), being also significant the dif-
ference. On day 21, the percentage of CD4+CD25+Foxp3+ 
cells in the treated group was significantly lower compared 
to that of the control group [Day 21: Cy, 0.2 (0.0–0.7) 
vs Control, 1.1 (0.3–6.3), P < 0.01] (Fig. 1, b). Moreover, 
CD4+CD25+IL-10+ cells increased their percentage du-
ring the studied period (P < 0.001), and the difference 
between the values on days 0 and 21 was significant 
[Day 0: 0.7 (0.1–1.0) vs. Day 21: 6.3 (1.0–7.4); P < 0.01]. 
Also, the percentage of circulating CD4+CD25+IL-10+ cells 
in the treated group was significantly lower with respect 
to the control group on the same day [0.7 (0.2–4.3) vs. 
6.3 (1.0–7.4), P < 0.05] (Fig. 1, c).
NKT I is a T cell subset with regulatory properties 
which can display an antitumor function. We aimed 
to study the variation of this cell population during tumor 
evolution. We observed that while from days 0 to 7 the % 
of NKT I cells increased significantly [12.4 (4.0–30.8) vs. 
17.8 (6.2–38.2)], (P < 0.001)], by day 14 those levels had 
already returned to the basal ones [8.3 (1.9–22.1)]. The 
analysis of the effect of Cy treatment on this cell popula-
tion showed that the treatment decreases its %, although 
not significantly, on day 21 [Day 21: Control 8.4 (3.8–19.3) 
vs Cy 3.7 (2.4–6.3)] (Fig. 2, a).
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Fig. 2. Effect of cyclophosphamide on circulating NKT I cells du-
ring tumor evolution [median (range)].  a) % of TCR+CD161+ cells, 
Kruskal — Wallis Test, P<0.001; Mann — Whitney Test, day 7 vs day 
14: P < 0.001; day 21 vs day 0: ns; day 21: Cy vs Cy-d: P < 0.01. b) 
co-evolution of Foxp3+ Tregs and NKT I cells during tumor evolution.
As NKT I and natural Tregs cells exert opposite 
actions on tumor development we depicted graphi-
cally their simultaneous variations along tumor evolu-
tion (Fig. 2, b). Both cell populations increased their 
respective levels until day 7. From that day on, while 
Tregs continue increasing their percentage, NKT I cells 
decreased, reaching levels even lowers than the basal 
ones.
Taking into account the lack of modulation of NKT 
I cells by the antimetastatic dose of Cy, we wanted to know 
if a different schedule or dose of Cy would be able to in-
crease this cell population. We decided to duplicate the 
dose previously used in a single injection (Cy-d):  when the 
single dose of Cy was duplicated (20 mg/kg instead of 10), 
a marginally significant increase in the percentage of NKT 
I cells with respect to the control group was observed 
[day 21: Control 8.4 (3.8–19.3) vs Cy-d 12.8 (3.5–20.7), 
P = 0.055] (Fig. 2, a). Interestingly, when comparing the 
effect caused on this cell population by a single Cy dose 
of 10 mg/kg with that of 20 mg/kg (Cy-d), the difference 
was significant (P < 0.01).
The idea that the immune system can recognize and 
destroy nascent transformed cells was originally integrat-
ed in the cancer immunosurveillance hypothesis posed 
by Burnet and Thomas in 1957 [34]. Almost half a century 
later, Schreiber and colleagues proposed that cancer im-
munosurveillance may function as the elimination phase 
of a process called cancer immunoediting. This process 
is responsible for eliminating tumors and sculpting the 
immunogenic phenotypes of tumors that eventually ap-
pear in immunocompetent hosts [35]. The importance 
of the antitumor immune response in determining the 
fate of an immunogenic tumor makes it interesting and 
necessary to study the modulation of different subsets 
of immune cells during tumor development.
CD4+CD25+ regulatory T cells NKT are two popula-
tions of T lymphocytes that can independently regulate 
adaptive and innate responses. Activated NKT cells 
seem to modulate quantitatively Treg function through 
IL-2-dependent mechanisms, whereas Tregs can sup-
press the proliferation, cytokine release and cytotoxic 
activity of NKT cells by cell-contact-dependent mecha-
nisms [36].
During L-TACB tumor evolution we observed an in-
crease in the levels of different subsets of CD4+CD25+ 
Tregs, namely CTLA-4+, Foxp3+ and IL-10+ cells. On the 
other hand, the significant increase in the percentage 
of NKT I cells demonstrated between days 0 and 7, 
was completely reversed by day 14, the level of this 
cells being even under the basal ones. Taking into 
consideration that natural Foxp3+ Tregs and NKT I cells 
exert opposite actions on tumor development, we were 
interested in learning about their simultaneous variation 
during tumor growth. We observed that in the first steps 
of tumor development both cell types, Tregs and NKT I, 
increased their levels, indicating the existence of a sort 
of a balance, at least partial, between these cells types 
with opposite effects. After that moment, the balance 
is broken because of a significant decrease of the NKT 
I population, while Tregs showed increased values 
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with respect to basal ones throughout the experiment, 
in spite of a transitory non significant decrease on day 
14, thus contributing to an immune response modu-
lated towards immunosuppression. We are aware that 
several other regulatory cell types may have influence 
in the modulation of the immune response to the tumor. 
Nevertheless, Tregs and NKT I represent two important 
cell types involved in innate immunity related to pro- and 
anti- tumor responses, respectively.
Both, experimental and clinical studies revealed 
that cyclophosphamide, an alkylating agent commonly 
used in cancer chemotherapy [22], exerts an apparently 
paradoxical effect in host immune response. High doses 
of Cy (i.e. MTD, maximum tolerated dose) bring about, 
along with a reduction of primary tumor mass, an im-
pairment of the host defense mechanisms, therefore 
leading to immunosuppression. However, the admin-
istration of low doses of Cy leads to an enhancement 
of the immune response, both in experimental animals 
and in humans, frequently causing tumor rejection[23, 
25, 28, 29].
Previously, we demonstrated that a single low-dose 
Cy, a treatment completely devoid of toxicity, inhibited 
metastasis development without affecting primary tu-
mor growth [26]. The antimetastatic action of Cy was 
mediated by immunomodulation since this effect could 
be adoptively transferred by immune cells of Cy-treated 
tumor-bearing rats and the same treatment did not have 
any effect in immunodeficient nude mice [27]. We dem-
onstrated that IL-10 was the main factor responsible for 
the  induction and development of immunosuppression 
in L-TACB-bearing hosts and that the antimetastatic im-
munomodulatory effect of cyclophosphamide was medi-
ated by a reduction in IL-10 levels produced by T-lym-
phocytes [28]. In fact, Cy induced a Th2/Th1 switch and 
increased the proliferative rate of spleen cells [30].
Interestingly, the present results showed that 
the antimetastatic dose of Cy (10mg/kg) induced 
a significant decrease of the CD4+CD25+Foxp3+ and 
CD4+CD25+IL-10+ cells. On the other hand, this treat-
ment was not able to change the levels of NKT I cells. 
Considering the lack of modulation of NKT I cells by the 
antimetastatic dose of Cy, we studied the level of that 
cell population after a single dose of 20 mg/kg Cy, and 
we observed an increase compared to the percentage 
obtained after the treatment with half a dose. Neverthe-
less, when compared to the control group, the difference 
was not significant. Therefore, the decrease of peripheral 
blood NKT I observed during L-TACB tumor growth could 
not been reverted by the different treatments utilized.
Hence, the antimetastatic effect of a single low dose 
of Cy would be due, at least in part, to downregulation 
of natural and inducible Treg cells. The importance of the 
innate antitumor immune response in general, and its 
modulation by treatments with low dose chemothera-
peutics in particular, warrants further studies in this area.
Our results may have importance on development 
of new therapies for metastatic lymphomas con-
sidering that a single low-dose cyclophosphamide, 
a treatment devoid of toxicity, would act inhibiting 
one of the mechanisms contributing to escape from 
immune rejection, thus inhibiting malignant growth 
and progression.
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